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Abstract
Testosterone deficiency syndrome (TDS) is a clinical and biochemical syndrome 
frequently associated with age and co-morbidities and is characterized by deficiency 
in testosterone and relevant androgen-deficiency symptoms. The main physiological 
action of testosterone in male sexual function is in sexual desire by regulating the 
timing of the penile erectile with sex. However sexual dysfunction associated with 
TDS also includes erectile dysfunction (ED) and delayed ejaculation. The link between 
ED, testosterone deficiency and cardiovascular disorders is well documented. The 
recommended tests for men with ED include fasting glucose, cholesterol, lipids and 
testosterone level. Both ED and TDS are treatable conditions. A range of testosterone 
preparations are available for supplementation, and the combination of testosterone 
replacement therapy and phosphodiesterase type 5 inhibitors might improve outcomes 
in some cases. The selection of the testosterone replacement therapy should be a joint 
decision between an informed patient and his primary care physician, and regular 
follow-up should be conducted to assess treatment efficacy and surveillance for 
adverse events. 
ABBREVIATIONS
TDS: Testosterone deficiency syndrome; ED: erectile 
dysfunction; PDE5: Phosphodiesterase inhibitor type 5
INTRODUCTION
Significant progress has been made in the field of medicine 
for erectile dysfunction (ED) since 1970s. In the past, male 
sexual dysfunction was thought to be purely psychogenic but 
increased understanding in the erectile physiology at molecular 
level has shown that testosterone deficiency plays a major role 
in sexual dysfunction. Men with low testosterone levels may 
often be overlooked as the association between testosterone 
deficiency syndrome (TDS) and its related co-morbidities 
such as cardiovascular disease and metabolic syndrome is not 
appreciated and at times, the symptoms and signs of TDS may 
not be obvious. This review article aims to provide primary 
care practitioners a practical approach to the diagnosis and 
management of testosterone deficiency in patients with ED.
Testosterone and ED
Testosterone is vital for normal functioning throughout a 
man’s life and a reduced testosterone level could compromise 
the man’s general well-being and his sexual function. Published 
literature showed that testosterone controls, directly or indirectly, 
several mechanisms pertinent to penile erectile function such as 
the promotion and differentiation of penile stem cells to penile 
smooth muscle cell phenotype, activity of cavernosal nitric oxide 
synthase and that of RhoA-kinase pathway [1]. More importantly, 
testosterone also regulates the expression of phosphodiesterase 
type 5 (PDE5), and in so doing maintains a homeostatic ratio 
between isoforms of nitric oxide synthase and PDE5 enzyme that 
is responsible for penile erection [2].  
Apart from penile erection, testosterone also regulates other 
aspects of male sexual desire. While erections are possible in 
hypogonadal conditions, studies showed that patients with 
decreasing levels of sexual desire have progressively lower 
concentrations of testosterone than men who maintain their 
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sexual desire. Sexual desire/libido is universally accepted as 
one of the most testosterone-dependent aspects of male sexual 
behaviors [3]. It appears that testosterone is responsible in the 
regulation of the timing of the erectile process as a function of 
sexual desire, thereby coordinating erection with sex [4]. Some 
studies showed that higher androgen level potentially play a 
dominant role in increased frequency of autoeroticism behaviors 
[5] and propensity for extramarital affairs [6]. Recent studies 
have also highlighted the role of testosterone in ejaculatory 
dysfunction via the effect of testosterone on nitric oxide 
metabolism in the central and peripheral control of ejaculation 
that could be accountable in condition such as premature 
ejaculation [7]. 
MATERIALS AND METHODS
Diagnosis of TDS
There is strong evidence that ED is an independent marker 
for subsequent cardiovascular disease and that the incidence of 
ED is more common in older patients with higher cardiovascular 
risks. The prevalence of low testosterone in men with ED has 
been estimated at 10-20% [8]. The association between ED, low 
testosterone level and cardiovascular disease are well recognized 
and these disorders are associated with the presence of metabolic 
syndrome [9]. In fact a clear negative relationship exists between 
the presence of the risk factors for metabolic syndrome and 
levels of circulating testosterone in patients with ED [9]. 
The clinical presentation of TDS, defined as both low 
testosterone level and clinically significant symptoms, can be at 
times nonspecific and often overlooked or under-diagnosed. The 
clinical symptoms associated with TDS can be divided into 3 main 
groups, namely psychosomatic, metabolic and sexual related 
problems. Unfortunately none of the symptoms is specific to the 
low androgen state but each symptom may raise the suspicion 
of TDS. 
Patients with ED, together with other symptoms such as 
reduced libido, decreased muscle mass and strength, presence 
of type 2 diabetes mellitus and metabolic syndrome should be 
screened for TDS (Figure 1). The initial assessment of subjects 
with clinical suspicion of TDS should include a comprehensive 
evaluation of medical and psychosocial, associated co-
morbidities as well as identification of any reversible factors and 
conditions that could impact on the prescription of testosterone 
replacement therapy (TRT) such as in subjects with undiagnosed 
prostate cancer, obstructive sleep apnea and congestive heart 
failure (Figure 1). While standardized questionnaires such as the 
Androgen Deficiency in Aging Male (ADAM) checklist is designed 
to identify symptoms and signs of TDS [10], they are not very 
specific but may play a role in encouraging men to discuss their 
symptoms and for monitoring changes in symptoms. Previously, 
a brief (12 items) structured interview called the ANDROTEST 
has been designed specifically to screen for hypogonadism in 
patients with sexual dysfunction [11]. 
Physical examination should focus on cognition, neurological, 
cardiovascular and urological findings. In men over the age 
of 40 years, prior to TRT, the risk of prostate cancer must be 
assessed and if the digital rectal examination of the prostate 
gland or prostate specific antigen (PSA) reading is abnormal, 
further urological assessment should be arranged [10]. The 
recommended tests for men with ED are fasting glucose, 
cholesterol, lipids and testosterone level. 
Laboratory diagnosis of testosterone deficiency: The 
exact pathogenesis of low testosterone remains contentious 
and several proposed mechanisms include decreased Leydig 
cell function, age-related increased in sex hormone binding 
globulin (which binds testosterone and lowers free bioavailable 
testosterone level), blunted circadian steady state of testosterone 
and decreased luteinizing hormone (LH) pulse by the 
hypothalamus [12]. 
The biochemical diagnosis of TDS is based on the measurement 
of serum total testosterone (TT), preferably before 11 am, though 
the diurnal rhythm of testosterone is less marked in men aged 
over 40 years. Transient decrease in serum testosterone level 
such as in acute physical illness should be excluded by careful 
evaluation and repeat testosterone measurement. Symptoms of 
TDS usually present with TT levels below 8 nmol/l (230 ng/dl), 
but may occur at various TT levels between 8 and 12 nmol/l (230 
to 350 ng/dl). As a general rule of thumb, the mean serum total 
testosterone decreases by 1% per year after the age of 40 years 
[13]. If the serum testosterone level is between 8 and 12 nmol/L, 
free testosterone (FT) level obtained by repeated measurements 
of TT with sex hormone binding globulin (SHBG) and albumin, or 
through equilibrium dialysis, may be helpful. 
While theoretically serum FT is more representative of 
the biological activity of testosterone, these assays may be 
more difficult to carry out (especially equilibrium dialysis, the 
reference method for FT), inaccurate (FT assay by testosterone 
analogue and ‘Free Androgen Index’), or can only be performed 
by some laboratories. Furthermore there are no accepted lower 
limits of free testosterone for the diagnosis of TDS [10]. The 
FT assays are generally set aside for the repeat assay and to 
certify the significance of a borderline TT level, or when SHBG 
concentration may be altered. 
In the case of low or borderline testosterone value, the assay 
should be repeated, because of the frequent intra-individual 
fluctuations of serum testosterone, unless physical evidence 
of hypogonadism (i.e. atrophied testes) is present. The assays 
of serum luteinizing hormone (LH) and follicle stimulating 
hormone (FSH) (to specify the primary/testicular or secondary/
hypothalamic or pituitary origin of hypogonadism), prolactin (to 
screen for hyperprolactinaemia), and possibly SHBG should be 
combined with the repeat testosterone assay. 
Testosterone Replacement Therapy 
Whilst there is no consensus on the lower limit of the normal 
range for testosterone, there is a general consensus that a 
total testosterone level above 12 nmol/L (350 ng/dl) does not 
warrant TRT [10]. Men with serum total testosterone levels 
below 8 nmol/L (230 ng/dl) will usually benefit from TRT. For 
men with borderline or low/normal TT (8-12 nmol/l or 230-350 
ng/dl), several meta-analyses have established that significant 
improvements may be achieved with TRT especially with regards 
to body composition and sexual function [14]. The indication to 
start TRT must be based on complete clinical assessment with an 
evidence of hypoandrogenism.
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History 
1. Medical History
2. Sexual History
3. Psychosocial history
4. Exclude reversible causes (such 
as medications etc)
Screening Questionnaire
1. Hypogonadism: e.g. ADAM 
2. ED specific: e.g. SHIM or IIEF-5
3. ED and hypogonadism: e.g. 
ANDROTEST
Physical Examination
- Signs of hypogonadism
- Cardiovascular findings
- Neurology findings
- Prostate examination
- Penile deformities
Standard Investigations
- Fasting lipid and cholesterol
- Fasting glucose 
- Morning serum total 
testosterone ± free testosterone 
level 
Successful outcome vs. 
Development or 
Progression of disease
Good 
response
Review & Follow up:
At 6 weeks
- Optimise co-morbidities
- Review testosterone level
and adjust TRT dose
- Monitor for side effects and 
perform DRE, PSA and hct
At 3-6 months
- Review testosterone level 
- Adjust TRT dose
- Monitor for side effects and
perform DRE, PSA and hct
Poor 
response 
Treatment of ED
1. General health education (eg. Stop smoking, 
physical exercise, lose weight etc)
2. Screen for medical conditions (such as cardiac, 
diabetes etc)
3. Correct/treat reversible causes (e.g. drugs etc)
4. Optimise current medical co-morbidities
5. Initiate pharmacotherapy: Combination of TRT 
and PDE5 inhibitor
- Hypoandrogenism:
- >12nmol/L Æ no TRT required
- <8nmol/L Æ Requires TRT
- 8-12nmol/L Æ Discussion about TRT 
trial
- Erectile Dysfunction: PDE5 inhibitor
Annual review
Consider Appropriate Referrals
1. Urology referral
- Management of ED, LUTS, 
PSA
- Second and third line treatment 
for ED
2. Endocrinology referral
- Further management of lipids, 
diabetes and osteoporosis
3. Cardiology referral
- Management of cardiovascular 
disease 
Figure 1 A practical algorithm for the management ED in suspected hypogonadal men. (ED- erectile dysfunction, ADAM- Androgen Deficiency in Aging Male, SHIM- 
Sexual Health Inventory in Male, IIEF- International Index of Erectile Function, T- testosterone, PDE- phosphodiesterase, LH- luteinising hormone, FSH- follicle stimulating 
hormone, DHEA- dihydroepiandrosterone, TSH- thyroid stimulating hormone, SHBG- sex hormone binding globulin, TRT- testosterone replacement therapy, SSRI- 
selective serotonin reuptake inhibitor, TCA- tricyclics antidepressant, PSA- prostate specific antigen, DRE- digital rectal examination, hct- hematocrit)
When choosing which TRT to prescribe, primary care 
physician must exercises good clinical judgment together with 
adequate knowledge of the advantages and drawbacks of TRT 
and considers the bioavailability, safety, tolerability, efficacy and 
preference of each TRT product (Table 1). Hypogonadal men 
restored to eugonadal state with TRT will experience improvement 
in sexual functions, particularly erectile, ejaculation, orgasm and 
penile sensations; and restored or enhanced responsiveness to 
PDE5 inhibitors [10]. The contraindications and cautions for 
the use of testosterone remain controversial. Men with severe 
lower urinary tract symptoms, polycythaemia (hematocrit 
>50%), untreated obstructive sleep apnoea, severe congestive 
cardiac failure, breast or prostate cancer should not be started 
on TRT without appropriate assessment and treatment by the 
respective specialists. The use of TRT in clinically symptomatic 
hypoandrogenism men treated previously for localized prostate 
cancer remains controversial [15]. The selection of the TRT 
preparation should be a joint decision between an informed 
patient and his physician. It is important to counsel younger men 
who wish to father children that exogenous TRT paradoxically 
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Delivery Method Half-life Strengths available Adverse Event
SC Implant 90 days
100mg
200mg
Twice per year administration. Placement is invasive with 
risk of extrusion and site infections
IM injection 14-21 days
100mg
250mg
Pain at injection site.
Fluctuation in testosterone level.
Transdermal Gel 6 hours 50mg in 5g sachet Possible transfer during intimate contact  
Transdermal solution 6 hours 30-120mg solution Possible transfer during intimate contact  
Transdermal Patches 10 hours
12.2mg (2.5mg/24hrs)
24.3mg (5mg/24hrs)
Skin irritation
Cream     6 hours
10mg/g (1% w/w)
20mg/g (2% w/w)
50mg/g (5% w/w)
Skin irritation
Depot Injection 4-5 days 250mg/1mL
Wild fluctuations in circulating testosterone levels
Relative higher risk of polycythemia
Oral Capsule 4 hours 40mg
Variable clinical response
First pass metabolism; must be taken with meals
IM Injection 34 days 1000mg/4mL Pain at injection site
Table 1: Various testosterone formulations.
Abbreviations: IM= Intra Muscular
results in infertility and this could potentially be irreversible. 
The effects of TRT may be perceived within 2-4 weeks, 
but sexual effects may sometimes take 3-6 months to become 
apparent and even up to 1 year for the nocturnal erections to 
reach normal range in previously untreated hypogonadal patients 
[16]. Some studies showed that TRT resulted in a significant but 
moderate improvement in all aspects of sexual function in men 
with testosterone at baseline (12 nmol/ml or 350 ng/dl) [17]. 
The magnitude of the effect on erectile function is inversely 
related to baseline concentration of testosterone. 
Since the occurrence of any adverse events during therapy 
(such as an elevated hematocrit or PSA) requires rapid 
discontinuation of TRT, short-acting preparation is preferred 
over long-acting depot preparation in the initial treatment of 
hypogonadal men, but there is no contraindication to start with 
longer acting preparations. At present the use of gonadotophic 
hormones such as human chorionic gonadotropin and selective 
estrogen receptor modulator (such as clomifene citrate) is not 
recommended except in selected cases of male infertility [18].  
Regular patient follow up is paramount following TRT 
initiation (Figure 1). Sustained supraphysiological levels of 
testosterone should be avoided. Failure to benefit after adequate 
testosterone treatment for 3 to 6 months should result in 
further investigation to rule out associated comorbidities 
and/ or discontinuation of TRT. Patients should be monitored 
at 3 months initially, and later at 3 to 6 monthly follow-up for 
adjustment of TRT and surveillance for any complication. Once 
a steady testosterone state is achieved, annual follow-up can be 
instituted. 
Testosterone & PDE5 Inhibitors in ED: As previously 
mentioned, testosterone modulates the expression of isoforms 
of nitric oxide synthase and PDE5 enzyme [19]. Several studies 
have demonstrated that TDS is associated with a reduced PDE5 
inhibitors efficacy [19]. This underlies the important concept that 
TDS must be ruled out, or if present, should be adequately treated, 
before PDE5 inhbitors are prescribed in men with ED. Published 
literature showed the combination of TRT and PDE5 inhibitors 
enhances the overall efficacy in men with were previously PDE5 
inhibitors unresponsive [19]. Longer duration of combination 
TRT and PDE5 inhibitors use appeares to increase the patient 
response rate to PDE5 inhibitors [20].  
At present controversies exist whether men with 
hypoandrogenism and ED should be treated initially with PDE5 
inhibitors, TRT or in combination [16]. While TRT should be 
considered as the first line treatment in patient with ED who 
have hypoandrogenism, this approach might not be adequate 
and/or appropriate as a monotherapy in all cases because of 
the multifactorial nature of ED. Furthermore, some studies have 
suggested that erectile response may actually decreased when 
higher levels of testosterone were reached in men who were not 
hypogonadal [21]. Hence, further studies are needed to evaluate 
the benefits of combination TRT and PDE5 inhibitors.   
CONCLUSIONS 
Mild hypogonadism/hypoandrogenism is not uncommon 
and the combination of symptoms and signs can assist in the 
identification of TDS. A biochemical confirmation of TDS is 
mandatory prior to TRT. Although hypoandrogenism can be the 
main cause of ED in younger patients, ED is often multi-factorial 
in pathophysiology and therefore it is unlikely that TDS is the 
sole contributor for the development and progression of ED. For 
this reason, combination therapy using TRT and PDE5 inhibitors 
should be considered as first line in the majority of cases as it 
might improve the clinical outcome better than TRT only.  
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